Involvement of the TNF-α/TGF-β/IDO axis in IVIg-induced immune tolerance

Cytokine

Volumn 71, Issue 2, 2015, Pages 181-187

  Loubaki, Lionel ^a   Chabot, Dominique ^a,b   Bazin, Renée ^a,b  

^a Department of Research and Development ^*  (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

IDO; Immunomodulation; Intravenous immunoglobulin; TGF beta; TNF alpha

Indexed keywords

IMMUNOGLOBULIN; INDOLEAMINE 2,3 DIOXYGENASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ARTICLE; CELL EXPANSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; MONOCYTE; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; CELL CULTURE; DRUG EFFECTS; FLOW CYTOMETRY; GENE EXPRESSION; GENETICS; IMMUNOLOGY; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

CELLS, CULTURED; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MONOCYTES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84911059093     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.10.016     Document Type: Article

References (54)

1. Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
2. Parihar A., Eubank T.D., Doseff A.I. Monocytes and macrophages regulate immunity through dynamic networks of survival and cell death. J Innate Immunol 2010, 2:204-215.
3. Li M.O., Wan Y.Y., Sanjabi S., Robertson A.K., Flavell R.A. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006, 24:99-146.
4. Takeuchi M., Alard P., Streilein J.W. TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells. J Immunol 1998, 160:1589-1597.
5. Du C., Sriram S. Mechanism of inhibition of LPS-induced IL-12p40 production by IL-10 and TGF-beta in ANA-1 cells. J Leukoc Biol 1998, 64:92-97.
6. Hara Y., Caspi R.R., Wiggert B., Dorf M., Streilein J.W. Analysis of an in vitro-generated signal that induces systemic immune deviation similar to that elicited by antigen injected into the anterior chamber of the eye. J Immunol 1992, 149:1531-1538.
7. Wilbanks G.A., Mammolenti M., Streilein J.W. Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-beta. Eur J Immunol 1992, 22:165-173.
8. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003, 198:1875-1886.
9. Hecker K.H., Niizeki H., Streilein J.W. Distinct roles for transforming growth factor-beta2 and tumour necrosis factor-alpha in immune deviation elicited by hapten-derivatized antigen-presenting cells. Immunology 1999, 96:372-380.
10. Masli S., Turpie B. Anti-inflammatory effects of tumour necrosis factor (TNF)-alpha are mediated via TNF-R2 (p75) in tolerogenic transforming growth factor-beta-treated antigen-presenting cells. Immunology 2009, 127:62-72.
11. Natoli G., Costanzo A., Guido F., Moretti F., Levrero M. Apoptotic, non-apoptotic, and anti-apoptotic pathways of tumor necrosis factor signalling. Biochem Pharmacol 1998, 56:915-920.
12. Magnusson C., Vaux D.L. Signalling by CD95 and TNF receptors: not only life and death. Immunol Cell Biol 1999, 77:41-46.
13. Lynch D.H. The role of FasL and TNF in the homeostatic regulation of immune responses. Adv Exp Med Biol 1996, 406:135-138.
14. Waetzig G.H., Rosenstiel P., Arlt A., Till A., Brautigam K., Schafer H., et al. Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factor-beta1. FASEB J 2005, 19:91-93.
15. Ware C.F., VanArsdale S., VanArsdale T.L. Apoptosis mediated by the TNF-related cytokine and receptor families. J Cell Biochem 1996, 60:47-55.
16. Luo X., Budihardjo I., Zou H., Slaughter C., Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998, 94:481-490.
17. Chen X., Baumel M., Mannel D.N., Howard O.M., Oppenheim J.J. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol 2007, 179:154-161.
18. Pallotta M.T., Orabona C., Volpi C., Vacca C., Belladonna M.L., Bianchi R., et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 2011, 12:870-878.
19. Fallarino F., Grohmann U., Puccetti P. Indoleamine 2,3-dioxygenase: from catalyst to signaling function. Eur J Immunol 2012, 42:1932-1937.
20. Mulley W.R., Nikolic-Paterson D.J. Indoleamine 2,3-dioxygenase in transplantation. Nephrology (Carlton) 2008, 13:204-211.
21. Mellor A.L., Munn D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004, 4:762-774.
22. Lemieux R., Bazin R., Neron S. Therapeutic intravenous immunoglobulins. Mol Immunol 2005, 42:839-848.
23. Gelfand E.W. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012, 367:2015-2025.
24. Nimmerjahn F., Ravetch J.V. FcgammaRs in health and disease. Curr Top Microbiol Immunol 2011, 350:105-125.
25. Schwab I., Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system?. Nat Rev Immunol 2013, 13:176-189.
26. Cousens L.P., Najafian N., Mingozzi F., Elyaman W., Mazer B., Moise L., et al. In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity. J Clin Immunol 2013, 33(Suppl 1). S43-9.
27. Massoud A.H., Guay J., Shalaby K.H., Bjur E., Ablona A., Chan D., et al. Intravenous immunoglobulin attenuates airway inflammation through induction of forkhead box protein 3-positive regulatory T cells. J Allergy Clin Immunol 2012, 129(1656-65):e3.
28. Olivito B., Taddio A., Simonini G., Massai C., Ciullini S., Gambineri E., et al. Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy. Clin Exp Rheumatol 2010, 28:93-97.
29. Cousens L.P., Tassone R., Mazer B.D., Ramachandiran V., Scott D.W., De Groot A.S. Tregitope update: mechanism of action parallels IVIg. Autoimmun Rev 2013, 12:436-443.
30. Su Y., Rossi R., De Groot A.S., Scott D.W. Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se. J Leukoc Biol 2013.
31. Neron S., Dussault N., Racine C. Whole-blood leukoreduction filters are a source for cryopreserved cells for phenotypic and functional investigations on peripheral blood lymphocytes. Transfusion 2006, 46:537-544.
32. Hainz U., Obexer P., Winkler C., Sedlmayr P., Takikawa O., Greinix H., et al. Monocyte-mediated T-cell suppression and augmented monocyte tryptophan catabolism after human hematopoietic stem-cell transplantation. Blood 2005, 105:4127-4134.
33. Imbach P., Wagner H.P., Berchtold W., Gaedicke G., Hirt A., Joller P., et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 1985, 2:464-468.
34. von Bubnoff D., Matz H., Frahnert C., Rao M.L., Hanau D., de la Salle H., et al. FcepsilonRI induces the tryptophan degradation pathway involved in regulating T cell responses. J Immunol. 2002, 169:1810-1816.
35. Pugliese A. Central and peripheral autoantigen presentation in immune tolerance. Immunology 2004, 111:138-146.
36. Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001, 345:747-755.
37. Nimmerjahn F., Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008, 26:513-533.
38. Tha-In T., Bayry J., Metselaar H.J., Kaveri S.V., Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008, 29:608-615.
39. Zambidis E.T., Scott D.W. Epitope-specific tolerance induction with an engineered immunoglobulin. Proc Natl Acad Sci USA 1996, 93:5019-5024.
40. Maddur M.S., Othy S., Hegde P., Vani J., Lacroix-Desmazes S., Bayry J., et al. Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol 2010, 30(Suppl 1):S4-S8.
41. Tang Q., Bluestone J.A. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008, 9:239-244.
42. Miyara M., Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007, 13:108-116.
43. Rissmann A., Pieper S., Adams I., Brune T., Wiemann D., Reinhold D. Increased blood plasma concentrations of TGF-beta1 and TGF-beta2 after treatment with intravenous immunoglobulins in childhood autoimmune diseases. Pediatr Allergy Immunol 2009, 20:261-265.
44. Reinhold D., Perlov E., Schrecke K., Kekow J., Brune T., Sailer M. Increased blood plasma concentrations of TGF-beta isoforms after treatment with intravenous immunoglobulins (i.v.IG) in patients with multiple sclerosis. J Neuroimmunol 2004, 152:191-194.
45. Govinden R., Bhoola K.D. Genealogy, expression, and cellular function of transforming growth factor-beta. Pharmacol Ther 2003, 98:257-265.
46. Zhang X.L., Selbi W., de la Motte C., Hascall V., Phillips A.O. Bone morphogenic protein-7 inhibits monocyte-stimulated TGF-beta1 generation in renal proximal tubular epithelial cells. J Am Soc Nephrol 2005, 16:79-89.
47. Debets J.M., Van de Winkel J.G., Ceuppens J.L., Dieteren I.E., Buurman W.A. Cross-linking of both Fc gamma RI and Fc gamma RII induces secretion of tumor necrosis factor by human monocytes, requiring high affinity Fc-Fc gamma R interactions. Functional activation of Fc gamma RII by treatment with proteases or neuraminidase. J Immunol 1990, 144:1304-1310.
48. Massoud A.H., Yona M., Xue D., Chouiali F., Alturaihi H., Ablona A., et al. Dendritic cell immunoreceptor: a novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells. J Allergy Clin Immunol 2014, 133(853-63):e5.
49. Geijtenbeek T.B., Gringhuis S.I. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 2009, 9:465-479.
50. Cope A.P., Liblau R.S., Yang X.D., Congia M., Laudanna C., Schreiber R.D., et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997, 185:1573-1584.
51. Chatzidakis I., Mamalaki C. T cells as sources and targets of TNF: implications for immunity and autoimmunity. Curr Dir Autoimmun 2010, 11:105-118.
52. Chen W. IDO: more than an enzyme. Nat Immunol 2011, 12:809-811.
53. Hoshino K., Sugiyama T., Matsumoto M., Tanaka T., Saito M., Hemmi H., et al. IkappaB kinase-alpha is critical for interferon-alpha production induced by Toll-like receptors 7 and 9. Nature 2006, 440:949-953.
54. Li Y., Tredget E.E., Ghahary A. Cell surface expression of MHC class I antigen is suppressed in indoleamine 2,3-dioxygenase genetically modified keratinocytes: implications in allogeneic skin substitute engraftment. Hum Immunol 2004, 65:114-123.